Company Overview and News
MIAMI, March 23, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) has enrolled the first patient in a Phase 2b dose escalation trial of OPK88003, a once-weekly oxyntomodulin therapy containing dual agonist activity towards GLP-1 and Glucagon receptors, to treat type 2 diabetes and obesity. Based on preclinical and Phase 2 data, the use of once-weekly dual agonists, such as OPK88003, could more effectively improve glucose control, increase weight loss and improve the lipid profile in type 2 diabetics compared to the current GLP—1 therapies on the market.
Whether you’re new to travel or you’ve already checked off a few destinations from your bucket list, you may be missing out on perks or deals if you’re not considering a travel agent.
The self-guided autonomous sailboat Ada, designed by students at UBC, is shown after it was recovered by the crew of the 'Neil Armstrong' research vessel off Florida on Dec. 1, 2017. (ADEON / University of New Hampshire)
Gaitrie Persaud didn't think she could go see Jay Z perform in Toronto next week — not because she's deaf but because she didn't know if the venue would provide the sign language interpreter she requires.
SANTA BARBARA, Calif., Sept. 27, 2017 /PRNewswire/ -- "More than one-fourth of all Americans may have dangerously high blood sugar levels and do not know it," says international health pioneer, Dr. Patricia Bragg, CEO of Bragg Live Food Products. (www.Bragg.com) "This often leads to type 2 diabetes, but there are simple things everyone can do right now to get healthy again!"
MINNEAPOLIS, Aug. 8, 2017 /PRNewswire/ -- ARKRAY USA, Inc., a leader in diabetes care products, announced today the launch of the GLUCOCARD Shine XL blood glucose monitoring system (BGMS). Highly accurate with a large LED screen, the GLUCOCARD Shine XL BGMS offers an ergonomic designed meter to provide a secure grip during testing. The large screen is intended to facilitate quick and easy viewing of blood glucose test results.
MINNEAPOLIS, Aug. 4, 2017 /PRNewswire/ -- ARKRAY USA, Inc., a leader in diabetes care products, announced today the launch of the ARK Care® Advance real-time diabetes management system and the ARK Care® Vita mobile app. Both systems are designed to help people with diabetes, and the healthcare professionals that care for them, have real-time access to blood glucose readings using an easy-to-use tool for monitoring and managing the disease.
A U.S. judge ruled on Thursday that a transgender woman could move forward with a sex discrimination lawsuit against her employer under the Americans with Disabilities Act, even though the ADA explicitly excludes transgender people from protection.
An Edmonton dentist named in a $26.5-million lawsuit filed by the family of a young girl who stopped breathing during an office visit says if he is found negligent, the girl's parents should share the blame.
A hearing has been set for Dr. William Mather, the Edmonton dentist charged with unprofessional conduct after administering a general anesthetic to a four-year-old patient who suffered a permanent brain injury.
WASHINGTON, Feb. 27, 2017 /PRNewswire-USNewswire/ -- The American Dental Association (ADA) commends the Environmental Protection Agency (EPA) for its scientifically sound decision today to deny a request to ban community water fluoridation. Hundreds of communities across the country optimally fluoridate their water supplies, providing an estimated 211 million people with increased protection from dental disease.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...